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1582 JOURNABSTRACT: Antibodies directed against tumor associated antigens are being increas-
ingly used for detection and treatment of cancers; however, there is an incomplete
understanding of the physiological determinants of antibody pharmacokinetics and
tumor distribution. The purpose of this study is to (a) compare the plasma pharmaco-
kinetics of T84.66, a monoclonal anti-CEA antibody directed against tumor associated
carcinoembryonic antigen (CEA), in control and CEA expressing LS174T xenograft
bearing mice, and (b) to develop a physiologically based pharmacokinetic (PBPK) model
capable of integrating the influence of CEA and the IgG salvage receptor, FcRn, on
T84.66 disposition. T84.66 pharmacokinetics were studied following i.v. administration
(1, 10, 25 mg/kg) in control and xenograft bearing mice. In control mice, no significant
differences in clearance were observed across the dose range studied. In mice bearing
xenograft tumors, clearance was increased by four- to sevenfold, suggesting the presence
of a ‘‘target mediated’’ elimination pathway. T84.66 plasma disposition was character-
ized with a PBPK model, and the model was applied to successfully predict antibody
concentrations in tumor tissue. The PBPK model will be used to assist in the develop-
ment of antibody-based targeting strategies for CEA-positive tumors.  2009 Wiley-Liss,
Inc. and the American Pharmacists Association J Pharm Sci 99:1582–1600, 2010Keywords: pharmacokinetics; physiological model; PBPK; T84.66 anti-CEA anti-
body; tumor associated antigen; carcinoembryonic antigen (CEA); target mediated
disposition; mathematical model; preclinical pharmacokineticsINTRODUCTION
Monoclonal antibodies1 have been investigated
for use as ‘‘magic bullets’’ to target a desired site
of action, while minimizing unwanted side
effects. The number of antibodies approved in
the oncology area has steadily increased over
recent years and, at present, nine monoclonal
antibodies have been FDA-approved for use innce to: Joseph P. Balthasar (Telephone: 716-
0; Fax: 716-645-3693; E-mail: jb@buffalo.edu)
aceutical Sciences, Vol. 99, 1582–1600 (2010)
, Inc. and the American Pharmacists Association
AL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARcancer treatment. More than 20 antibodies aimed
at different antigen targets are presently in
clinical oncology trials.2
Immune gamma globulin (IgG) is the most
prevalent antibody isotype found in man,
with average serum concentrations in the range
of 10–12 mg/mL.3 Virtually all mAb that are in
development are IgG antibodies. Compared to
other immunoglobulin isotypes, IgG has the
longest half-life and lowest fractional catabolic
rate.4 In 1964, Brambell proposed that specific
transport proteins were capable of binding to
IgG and limiting its elimination. With increasing
IgG concentrations, these receptors would getCH 2010
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face catabolism.5 Further research has led to the
isolation and cloning of this transport protein, and
it has been named ‘‘FcRn’’ or the Fc-receptor of
the neonate.6,7 Various groups have now demon-
strated the role of FcRn as a salvage receptor
protecting IgG from elimination.8–10 FcRn has
been shown to be expressed in the vascular
endothelial cells of various tissues and plays a
key role in maintaining IgG homeostasis. How-
ever, in addition to FcRn, interaction of an
antibody with its target antigen may be a very
important determinant of antibody disposition.11
A number of FDA-approved mAb demonstrate
‘‘target mediated elimination,’’12 where antibody
elimination is mediated by specific binding to
targets such as epidermal growth factor receptor
(EGFR), CD33, CD11 and Her2.11,13 Carcinoem-
bryonic antigen (CEA)14 is one of the most widely
studied tumor-associated antigens, and it is
known to be expressed at low levels in normal
tissues such as epithelial cells of the esophagus,
pancreas, uterus and prostrate, mucous stomach
cells and ducts of sweat glands.15–18 CEA levels
are increased by several fold in a wide range
of adenocarcinomas including breast cancers,
colorectal cancers, and other cancers of the
gastrointestinal tract. Their differential expres-
sion offers a possibility for discrimination between
normal tissues and tumor cells, making CEA an
extremely attractive target for antibody-directed
tumor imaging19–21 or drug targeting.22,23 How-
ever, the influence of tumor-associated CEA on
the plasma pharmacokinetics of anti-CEA anti-
bodies has not been thoroughly investigated.
In this work, we have developed a physiologi-
cally based pharmacokinetic (PBPK) model incor-
porating a target-mediated disposition component
to examine the influence of antigen–antibody
interaction on antibody pharmacokinetics. The
model also incorporates additional, known com-
plexities associated with antibody disposition
such as: convective uptake into tissues, FcRn-
mediated protection within endosomes of the
vascular endothelium, and the influence of
endogenous antibody levels on the FcRn-mediated
transport of therapeutic antibody. Plasma con-
centration data were collected from mice bearing
tumors expressing CEA and control mice lacking
the tumor-associated antigen. The PBPK model
was able to capture the plasma data in control
mice and in antigen-positive tumor-bearing mice,
and the model was shown to predict T84.66
antibody concentrations within tumor tissue.DOI 10.1002/jps JOUMATERIALS AND METHODS
Production and Purification of T84.66
Hybridoma cells producing T84.66, a monoclonal
anti-CEA antibody, were purchased from the
American Type Culture Collection (ATCC # HB-
8747, Manassas, VA). T84.66 is known to bind
CEA with an equilibrium dissociation constant of
3.8 1011 M.24 For the purposes of antibody
production, cells were grown in 1L spinner flasks
containing serum free media (Hybridoma SFM,
Invitrogen, NY), and culture supernatant was
harvested 2–3 times weekly. Anti-CEA antibody
was purified from culture supernatant by protein G
chromatography (Amersham Biosciences, Uppsala,
Sweden) by use of a Bio-Rad medium pressure
chromatography system (Bio-Rad, Hercules, CA).LS174T Adenocarcinoma Cells
LS174T human colon cancer cells (ATCC# CL-
188, Manassas, VA), which are known to express
CEA, were cultured in Minimum Essential Media
(MEM) supplemented with 10% fetal bovine
serum (Invitrogen, Grand Island, NY). Cells were
detached by tapping culture flasks, suspended
in sterile saline, counted, and used to establish
xenografts.Animals
Male athymic nude mice (20–25 g, 5–6 weeks old)
were obtained from Harlan (Indianapolis, IN).
Mice were housed in a sterile room, handled under
aseptic conditions in a laminar hood, and fed
autoclaved chow. 100mL of LS174T cells in
suspension (5 106 cells) were injected s.c. into
the right flank of the mice. Mice were monitored
regularly to check for tumor growth and body
weight. The tumor size was measured by vernier
calipers, and tumor volume was defined by the
standard formula; lw2/2, where l represents the
length of the longest diameter (mm) and where w
represents the length of the axis perpendicular to
l. All animal procedures were approved by the
Institutional Animal Use and Care Committee of
the University at Buffalo.Pharmacokinetic Study
T84.66 was administered intravenously via penile
vein injection to xenograft-bearing mice (startingRNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARCH 2010
1584 URVA, YANG, AND BALTHASARtumor volume 500–600 mm3) and to control
athymic mice at three dose levels: 1, 10, and
25 mg/kg (n¼ 4/group). Blood samples, 25mL,
were collected from the retro-orbital plexus
using calibrated capillary pipettes (Drummond
Scientific Company, Cat # 2-000-020) that were
prerinsed with EDTA. Samples were collected at
1 h, 3 h, 8 h, 1 day, 2 days, 4 days, 7 days, 12 days,
21 days, and 35 days from control athymic mice
and at 1 h, 3 h, 8 h, 1 day, 2 days, 4 days, 7 days,
and 12 days from xenograft-bearing mice. Blood
was centrifuged at 13,000 rpm for 3 min and the
plasma fraction was separated and stored at
208C.ELISA Procedure
T84.66 concentrations in mouse plasma were
determined by an ELISA method. Briefly, Nunc
Maxisorp 96-well plates (model # 62409-002,
VWR, Bridgeport, NJ) were coated with recombi-
nant carcinoembryonic antigen (Protein Sciences
Corporation, 400 ng/mL in 20 mM Na2HPO4,
250mL/well) and incubated at 48C overnight.
Samples and standards (200mL) were added in
triplicate and incubated for 2 h at room tempera-
ture. Goat anti-mouse-fab alkaline phosphatase
conjugate (Sigma, St. Louis, MO, Cat #A1682,
1:500 in PB-Tween, 100mL/well) was added to the
wells and allowed to incubate for 1 h at room
temperature. P-nitro phenyl phosphate (Peirce,
Rockford, IL, 4 mg/mL in diethanolamine buffer,
pH 9.8, 0.2 mL) was added to each well and the
change in absorbance at 405 nm with time was
monitored using the kinetic mode of a microplate
reader (Spectra Max 250, Molecular Devices,
Sunnyvale, CA). Standards were prepared by
diluting stock solutions of anti-CEA IgG to
appropriate concentrations (25–200 ng/mL) using
phosphate buffered saline (pH 7.4) and mouse
plasma (1% final v/v). Standard curves were linear
in this concentration range. Intra-assay and inter-
assay recoveries were within 90–110% and the
associated variability at the limit of quantification
(25 ng/mL) was less than 15%. Of note, the assay
has been validated for accurate recovery of anti-
CEA IgG in the presence of soluble (e.g., ‘‘shed’’)
CEA in plasma. CEA concentrations up to 5 ng/mL
do not lead to significant alteration in the
accuracy or precision of assay of T84.66 in mouse
plasma samples. Additionally, in preliminary
studies conducted with untreated mice bearing
LS174T xenografts, no animals were found toJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARCH 2010exhibit plasma CEA concentrations greater than
2 ng/mL.Data Analysis
Pharmacokinetic parameters of T84.66 were
initially estimated by noncompartmental phar-
macokinetic analysis using WinNonlin, version
5.0 (Pharsight Corporation, Palo Alto, CA). The
area under the concentration time curve to the
last observable point (AUClast) was estimated by
the trapezoidal rule. Terminal half-life (t1/2) was
obtained from the terminal linear portion of the
concentration–time curves.Mathematical Modeling
Our lab has previously published a PBPK
model that describes the role of FcRn as a
determinant of the plasma and tissue disposition
of IgG.25 In the present work, the basic PBPK
model has been revised and extended to incorpo-
rate a target-mediated elimination component to
characterize the influence of specific antigen–
antibody interactions on antibody disposition.
Organs and tissues included in the PBPK model
are plasma, lung, liver, gut, spleen, heart, muscle,
skin, kidneys, and tumor. These organs were
connected in an anatomical manner, as shown in
Figure 1. Each organ was further divided into
vascular, endosomal, and interstitial compart-
ments (Fig. 2a). The ‘‘endosomal’’ compartment
represents the endosomal volume within the
vascular endothelium of each tissue. The tumor
compartment includes a cell-space region that
contains the tumor-associated CEA (Fig. 2b). The
model was constructed to allow interaction of
T84.66 with a fraction of the total CEA in the
tumor, consistent with limited accessibility of
antibody to all regions of a solid tumor.
The model incorporates key features related to
IgG disposition such as (i) uptake of IgG from
the vascular layer and interstitial cell layer by
fluid- phase endocytosis,26–29 (ii) FcRn-mediated
salvage of IgG in the endosomal layer of the
endothelial cells in each organ,30–32 (iii) elimina-
tion of unbound IgG from all organs,31 (iv)
convective transport of IgG via paracellular pores
from the vascular to interstitial cell layer,32–34 (v)
the influence of CEA on antibody distribution and
elimination, and (vi) transport of IgG from the
interstitial space back to the systemic circulation
via the lymphatic system.32,34 In the previouslyDOI 10.1002/jps
Figure 1. Physiologically based pharmacokinetic
(PBPK) model of T84.66, monoclonal anti-CEA antibody
disposition. All major organs are connected in an ana-
tomical fashion with plasma flow represented by solid
arrows and lymph flow by dashed arrows. Each organ
compartment is divided into sub-compartments as
shown in Figure 2.
Figure 2. Intra-tissue sub-compartmental model for
T84.66 disposition. (a) Nontumor tissues. Each organ in
the model is divided into three sub-compartments
representing a vascular space, an endothelial endoso-
mal space, and interstitial space. Q and L represent the
plasma and lymph flow rates. sV,organ and sI,organ are the
vascular and lymphatic reflection coefficients, and R1 is
the rate of uptake and return of IgG from the vascular
and interstitial compartments into the endosomal
space. Kd is the dissociation constant for antibody bind-
ing to FcRn, which is present in the endosomal space of
each organ. FR represents the fraction of FcRn-bound
antibody that is recycled to the vascular space, and fu is
the unbound fraction of antibody. CLorgan is the clear-
ance of unbound IgG from the endosomal space of each
organ. (b) Tumor tissue. The tumor compartment is
divided into four sub-compartments comprising of the
vascular space, an endothelial endosomal space, an
interstitial space, and space associated with tumor cells.
In addition to the parameters described for nontumor
tissues, tumor parameters include the equilibrium dis-
sociation constant for IgG-CEA binding (Kd-CEA), the
fraction of IgG not bound to CEA (fuinter), and the
clearance of the IgG bound to CEA (CLTMD).
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR T84.66 1585published model, the lymph outflow from the
interstitial layer of each organ was assumed to
drain directly into the plasma compartment. In
the present model, we have incorporated a transit
compartment to represent lymph nodes, which
collect the lymphatic drainage from all organs
before returning lymph fluid to the systemic
circulation. The parameters and variables used
in the model are defined in Appendix I and
the equations for the model are provided in
Appendix II.
Shown below is a representative mass balance





¼ ðQorgan  CplasmaÞ
þ ððFR  R1  ð1  fuorganÞÞ  CTotalEndoOrgan
 VEorganÞ  ðR1  CVorgan  VVorganÞ
 ðð1  sVorganÞ  Lorgan  CVorganÞ
 ððQorgan  LorganÞ  CVorganÞDOI 10.1002/jps JOUIn this equation, Qorgan is the blood flow to the
vascular compartment and Cplasma refers to the
antibody concentration in plasma. The fraction of
antibody bound (1 fuorgan) to the FcRn receptor
is returned to the vascular compartment by rate
constant R1. IgG in the vascular space may be
taken up into the endosomal compartment by
the rate constant R1, and vascular IgG may be
transported to the interstitial space of the organ
via convection, as determined by the vascular
reflection coefficient (sV,organ) and the flow rate ofRNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARCH 2010
1586 URVA, YANG, AND BALTHASARlymph fluid (Lorgan). IgG may also exit the
vascular compartment via blood flow returning
back to systemic circulation, where the plasma
flow out of the organ is equal to the plasma flow
into the organ minus the lymph flow rate
(QorganLorgan).Figure 3. LS174T tumor growth curve. The increase
in tumor volume with time was captured with an
exponential growth function, y¼ a ebx, where y¼ tumor
tumor volume, a¼ initial tumor volume, x¼ time of
measurement, and b¼ exponent of tumor growth. The
fit growth function was used in the PBPK model to
increase tumor compartment volumes as a function of
time. All other tumor parameters were either constant
with tumor volume (e.g., sV,organ, sI,organ, etc.) or set as a
fixed function of tumor volume (e.g., FcRn mediated
organ clearance, CLorgan).Model Parameters
The physiological parameters for plasma flow
rates and vascular, interstitial and total organ
volumes were obtained from the literature.35 The
lymph flow rates were set to 2% for visceral organs
and 4% for muscle and skin.33 Endosomal volumes
for each organ was fixed to 0.5% of total organ
volume.25 The equilibrium dissociation constant
for IgG binding to FcRn was obtained from the
literature.36 The vascular reflection coefficient
and lymph reflection coefficient values were set to
0.95 and 0.2.25 These values were assumed to be
the same for all organs. Endogenous antibody
production was assumed to occur by a zero-order
rate process, K0. The value for this parameter,
1.63 1012 M/min, was defined through an
iterative process, where K0 was adjusted to
achieve a steady-state plasma concentration of
endogenous IgG of 14.7mM. Also through this
process, the model structure was used to define
steady-state endogenous IgG concentrations in all
model compartments, and these values were used
in subsequent modeling work as the ‘‘initial
conditions’’ of all differential equations for endo-
genous IgG.
IgG clearance from each organ was calculated
based on total intrinsic clearance values obtained
from a mechanistic model previously developed in
our laboratory.37 Individual organ clearances
were obtained by fractioning the total clearance
into organ clearances based on the tissue size.
Based on our previous model, the estimated
value for the rate of uptake into the endosomal
compartment (R1) and rate of recycling (R2) were
1.96 (1/day) and 20.4 (1/day), respectively. Since
the rate of recycling appears to be extremely fast
compared to the uptake rate, we decided to use a
single unifying rate constant, R1 to describe the
uptake of IgG into the endosomal compartment
and its return back to the vascular compartment.
The value for the rate constant R1 was obtained
by fitting the PBPK model to T84.66 plasma
concentration data from control mice. The value
for the recycling fraction (FR) was fixed at
0.715 based on our previous model, and theJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARCH 2010volume for the lymph node compartment was
assumed to be equal to volume of spleen.38 An
estimate for transit time associated with the
lymph node (Tau) was not available from the
literature, and was obtained by fitting the PBPK
model to the T84.66 plasma concentration data.Parameters for the Tumor Compartment
The rate of plasma flow to the tumor was obtained
from literature,32 and the tumor lymph flow rate
was set to 4% of the plasma flow rate. The total
tumor volume was defined through the use of an
exponential growth function, based on in vivo
measurements of tumor growth (Fig. 3). Tumor
volume at any given time (TVt) was defined as
the initial tumor volume, TV0, multiplied by
exp((0.0000635 time)). Relative to the total
tumor volume, the vascular volume was fixed
at 7%, the interstitial volume at 55%,32 and the
endosomal volume was fixed at 0.5%. The lymph
reflection coefficient was fixed to 0.2. Given
that tumor vasculature has been noted to be
more heterogeneous and more porous than
vessels associated with healthy tissues, we expect
that the value for tumor reflection coefficient
(stumor) would be lower than the reflection
coefficient associated with normal tissues. stumorDOI 10.1002/jps
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tumor bearing mice.
The dissociation constant for IgG interaction
with CEA was fixed at 3.8 1011 M,24 and the
concentration of CEA in the tumor compartment
was fixed at 110mg/g.39 The influence of CEA
on the clearance of T84.66 was modeled such
that T84.66 bound to CEA would be available
for target-mediated elimination, and unbound
T84.66 would be available for removal from the
tumor via the outflow of lymph fluid. Several
studies previously published in the literature
suggest that antibodies directed against tumor
associated antigens may not distribute homo-
genously due to transport barriers, heterogeneous
distribution of tumor associated antigens,40
and due to a possible ‘‘binding-site barrier.’’41
To account for limited accessibility of CEA to
T84.66 in the interstitial fluid of the tumor, an
accessibility parameter (FA) was incorporated
into the model, and estimated by fitting to the
observed concentration data. The fraction of
antibody unbound to FcRn (fuorgan) and the
total antibody concentration in the endosomal
space are defined by Eqs. (15)–(17) in Appendix II.
The fraction of antibody in the tumor interstitial
space that is not bound to CEA (fuinter) is
defined by Eqs. (18) and (19) in Appendix II.
Table 1 lists the parameters used in the
model and provides references to any literature















Lung 4.16 0.0842 0.191 0.0
GI 0.9 0.018 3.45 0.1
Liver 1.1 0.022 0.951 0.0
Spleen 0.05 0.001 0.10 0.0
Heart 0.28 0.0056 0.133 0.0
Kidney 0.80 0.016 0.298 0.0
Skin 1.21 0.0484 2.94 0.2
Muscle 0.80 0.032 7.924 0.1
Tumor 0.10 0.004
aFrom Baxter et al.32
bFrom Covell et al.33
cAssumed to be 0.5% of tissue volume.
dFrom Hansen and Balthasar.42
DOI 10.1002/jps JOUParameter Estimation
Unknown model parameters were R1, the rate
constant of uptake and return of IgG from
the endosomal space, and Tau, the transit time
associated with lymphatic transit. These two
unknown parameters were fitted to the plasma
data obtained from control animals at three dose
levels: 1, 10, and 25 mg/kg. The parameters
were fit to the data sets simultaneously using
maximum likelihood estimation of the ADAPT II
program43 with the following variance model:
VarðtÞ ¼ ðsinter þ sslopeYðtÞÞ2
Y(t) is the model output at time t and Var(t) is the
variance associated with the output. sinter and
sslope are the two variance parameters represent-
ing a linear relationship between the SD of the
model output and Y(t).
Parameter values for R1 and Tau were then
fixed, and unknown parameters associated with
the tumor compartment were fitted. Unknown
tumor parameters were the clearance of T84.66
bound to tumor antigens (CLTMD), the CEA
accessibility parameter for antibody–antigen
interaction (FA), and the reflection coefficient
for the tumor vascular space (stumor). Parameters
were estimated with simultaneous fitting to
plasma data obtained from LS174T xenograft-
bearing mice, using data from three dose levels










191 0.057 9.55E04 1.43E06
0 0.600 1.73E02 2.58E05
95 0.190 4.76E03 7.10E06
10 0.020 5.00E04 7.47E07
07 0.019 6.65E04 9.93E07
3 0.101 1.49E03 2.22E06
0 0.999 1.47E02 2.19E05
5 1.032 3.96E02 5.92E05
Function of tumor growth
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observation was weighted to inverse of the
variance of the output error (1/s2).Sensitivity Analysis
The sensitivity of model output to model para-
meters was assessed by evaluating the percentage
change in plasma AUC with the alteration of
model parameters by 10%:
%Change ¼ AUCSIM  AUC10%
AUCSIM
 100
AUCSIM refers to the AUC obtained with the
optimized parameters and AUC10% is the AUC
obtained following a 10% increase or decrease
in the parameter value.44 The analyses were
performed with simulated administration of
25 mg/kg T84.66.Model Evaluation
To test the prediction capability of the PBPK
model, tumor concentrations of T84.66 were
determined in a separate study following admini-
stration of 1 and 10 mg/kg doses of radiolabeled
T84.66. Observed tumor concentrations were
compared with model simulated values.
T84.66 was labeled with Iodine-125 (Perkin
Elmer Life & Analytical Sciences, Waltham, MA)
using a modified Chloramine-T method.45 Briefly,
10mL of 125I (100 mCi/mL) was added to 40mL of
T84.66 (1 mg/mL in phosphate buffered saline).
The reaction was initiated by addition of 20mL of
1 mg/mL chloramine-T in phosphate buffer. After
90 s, the reaction was stopped by addition of 25mL
sodium metabisulfite (2 mg/mL) in phosphate
buffer followed by 40mL of 10 mg/mL potassium
iodide in double distilled water. The reaction
mixture was lightly vortexed and immediately
loaded on a Sephadex G-25M prepacked column
(GE Healthcare, Uppsala, Sweden). Labeled anti-
body was collected in 500mL fractions and 1mL
samples were obtained from each fraction to
determine location of the labeled antibody peak.
The labeled antibody was stored at 48C until used.
The radiochemical purity of 125I-IgG was
determined by instant thin layer chromatography
(ITLC). One microliter of radiolabeled anti-CEA
IgG was spotted at the lower bottom end of the
ITLC plate. Eighty-five percent methanol was
used as the mobile phase for plate development
and strips cut from the plate were read on aJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARCH 2010gamma counter. The percentage of bound 125I was
calculated from the quotient of radioactivity in the
bottom section of the plate to the amount of
radioactivity in the entire plate. Radiochemical
purity of the labeled antibody preparation was
greater than 98%.T84.66 Tumor Concentrations in Mice
LS174T xenografts were established in male
athymic nude mice as described above. Two days
before administration of 125I–T84.66, study ani-
mals were given potassium iodide (0.2 g/L) in their
autoclaved drinking water to block the thyroid
uptake of 125I. 125I-labeled T84.66 was adminis-
tered via penile vein injection to xenograft-
bearing mice at 1 and 10 mg/kg (125I activity
10mCi/mouse) to 6 mice per dose level. At 30 min
and 7 days following T84.66 administration,
groups of three mice from each dose group were
sacrificed. Blood was obtained by cardiac punc-
ture, and tumor tissue was excised and weighed in
plastic culture tubes. Radioactive counts were
determined by gamma counting, and corrected for
background and decay.RESULTS
T84.66 plasma pharmacokinetics were studied at
1, 10, and 25 mg/kg dose levels in control and
LS174T adenocarcinoma-bearing Foxnu athymic
mice. T84.66 clearance in control mice at 1, 10,
and 25 mg/kg was 0.181 0.097, 0.283 0.051,
and 0.211 0.056 mL/h/kg. ANOVA did not iden-
tify significant differences between these clear-
ance values (p> 0.05). PBPK model parameters
R1 and Tau were fit to the plasma data obtained
from the three doses (simultaneously). The model
provided good fits for the control plasma data at all
doses as shown in Figure 4, and the best fit values
of the parameters with the associated CV% were
R1: 0.715 day
1 (0.112%) and Tau: 2.12 h (10%).
In xenograft-bearing mice, T84.66 doses of 1, 10,
and 25 mg/kg were associated with time-averaged
clearance values of 1.40 0.23, 0.977 0.19, and
0.973 0.33 mL/h/kg, respectively. At each dose
level, clearance was significantly greater than the
clearance observed at the corresponding dose in
control mice (p< 0.05).
The three unknown parameters of the tumor
model, that is, the vascular reflection coefficient
of the tumor compartment (stumor), clearance ofDOI 10.1002/jps
Figure 4. T84.66, anti-CEA antibody pharma-
cokinetics in mice. T84.66 was administered to Foxnu
athymic mice at three dose levels, 1 mg/kg (circles),
10 mg/kg (squares), and 25 mg/kg (triangles). Unknown
model parameters, R1 and Tau, were fit to all data sets
simultaneously. Solid lines denote the best fit obtained
from the PBPK model. Each symbol represents
the mean concentration, and error bars indicate the
standard deviation (n¼ 4).
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR T84.66 1589anti-CEA IgG due to specific binding to CEA
(CLTMD), and the CEA accessibility parameter
(FA, which represents the fraction of CEA
available for binding to antibody), were estimated
with good precision. The best-fit values were
stumor: 0.842 (0.374%), CLTMD: 0.166 mL/min
(5.33%), and FA: 0.203 (3.95%). The final model
provided good characterization of the data
obtained from all dose-levels administered in
control and tumor-bearing mice (Fig. 5a–c). All
estimated parameters and associated CV% values
are listed in Table 2.
The model structure and parameters were
employed to simulate the relationship of tumor
and plasma concentrations, to predict the extent
of binding of tumor CEA to antibody (i.e., receptor
occupation), and to determine the contribution of
CEA-mediated clearance of T84.66 to the total
elimination of the antibody. The percent contribu-
tion of CEA-mediated elimination of T84.66
decreased from 86% at the 1 mg/kg dose to 81%
and 65% at the 10 and 25 mg/kg doses, respec-
tively. As such, the contribution of the target
mediated clearance pathway was greatest at the
lowest dose, consistent with increased saturation
of CEA with increasing doses. Figure 6 presents
model-simulated dose-normalized plasma T84.66
concentrations in tumor bearing mice and control
mice, facilitating the visualization of the dose
dependency in T84.66 pharmacokinetics. TheDOI 10.1002/jps JOUtime-course of tumor to plasma T84.66 concentra-
tion ratios, following simulated doses of 1, 10, and
25 mg/kg, are shown in Figure 7. Due to relatively
slow entry of antibody into the tumor interstitial
fluid, and due to rapid CEA-mediated clearance,
the model predicts a low ratio of tumor to blood
concentrations of antibody. Interestingly, the
highest dose of T84.66, 25 mg/kg, was predicted
to lead to the highest tumor:blood concentration
ratio at early time points relative to dosing.
This prediction, which is opposite of the intuitive
expectation for decreased tumor selectivity with
increasing dose or concentration (due saturation
of antibody binding to CEA), is indicating that
CEA-mediated clearance of T84.66 from tumor is
playing the dominant role in determining T84.66
tumor concentrations. At high concentrations,
where CEA-T84.66 binding is saturated, CEA-
mediated clearance is less efficient, and this leads
to higher tumor:blood concentration ratios.Sensitivity Analysis
A sensitivity analysis was conducted to determine
the parameters to which the T84.66 plasma
concentration output is most sensitive. The
results from the sensitivity analysis were based
on the percent change in the area under the
plasma concentration curve (AUC) for T84.66
following a simulated 25 mg/kg dose (Fig. 8).
Small absolute values for percent change in AUC
indicate insensitivity to that parameter; negative
values for percent change indicate a decrease in
plasma AUC with an increase in the parameter.
The sensitivity analysis showed that the vascular
reflection coefficient (sV,organ), tumor vascular
reflection coefficient (stumor), concentration of
tumor associated antigen CEA (nPtCEA), antigen
accessibility parameter (FA) and total tumor
volume (Vtumor) were key parameters influencing
plasma antibody concentration. Moderate sensi-
tivity was observed for the parameters represent-
ing blood flow to the tumor compartment (Qtumor),
clearance of CEA-T84.66 complexes (CLTMD),
lymph flow transit time (Tau), the lymphatic
reflection coefficient (sI,organ), the rate constant for
IgG uptake into the endosomal compartment (R1),
tissue FcRn concentration (nPtorgan), and the
antibody recycling fraction (FR). Plasma antibody
concentrations were relatively insensitive to
changes in dissociation constant for IgG-FcRn
binding (Kd) and IgG-CEA binding (Kd-CEA).RNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARCH 2010
Figure 5. Comparison of T84.66 disposition in control and LS174T xenograft-bearing
mice. (a) Solid circles represent plasma T84.66 concentration data collected from control
mice and open circles represent mean data obtained from tumor bearing mice following
intravenous administration of 1 mg/kg T84.66. (b) Solid squares represent plasma
T84.66 concentration data collected from control mice and open squares represent
mean data obtained from tumor bearing mice following intravenous administration
of 10 mg/kg T84.66. (c) Solid triangles represent plasma T84.66 concentration data
collected from control mice and open triangles represent mean data obtained from tumor
bearing mice following intravenous administration of 25 mg/kg T84.66. The solid lines
represent the best fit obtained from the PBPK model. Each symbol represents mean
plasma concentrations, as measured by ELISA, and error bars indicate standard
deviations associated with each mean (n¼ 3–4).
1590 URVA, YANG, AND BALTHASARModel Evaluation: Comparison of Model
Simulated Tumor T84.66 Concentrations
With Observed Data
The physiologically based pharmacokinetic (PBPK)
model was developed based on plasma concentra-
tions of T84.66 obtained following antibody admin-
istration to mice with or without CEA-expressing
LS174T xenografts. Antibody concentrations in
tissues, including tumor tissue, were not available,JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARCH 2010and model fitting was based solely through the use
of plasma data. To evaluate the predictive capability
of the PBPK model, tumor concentrations were
determined following administration of T84.66,
at doses of 1 and 10 mg/kg, in a separate model
evaluation experiment. As shown in Figure 9, the
observed data were in good agreement with the
model predictions at the time points studied (30 min
and 7 days). T84.66 concentrations in other tissues
were not determined.DOI 10.1002/jps
Table 2. Parameters Estimated from the PBPK
Model
Parameter Model Estimates (%CV)
FR 0.715f
Parameters associated with basic PBPK model
Tau (h) 2.12e (0.122)
R1 (1/day) 0.715e (10.0)
Parameter associated with tumor compartment
CLTMD (mL/min) 0.166e (0.374)
FA 0.203e (5.33)
stumor 0.842e (3.95)
f, parameter value fixed to estimate obtained from Garg and
Balthasar.25 e, parameters estimated in current model.
Figure 7. Comparison of simulated tumor-to-plasma
ratios of T84.66 at 1, 10, and 25 mg/kg dose levels. Model
predictions are indicated with the short dashed line
(1 mg/kg dose), the long dashed line (10 mg/kg), and
with the solid line (25 mg/kg).
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR T84.66 1591DISCUSSION
Antibodies are capable of selectively targeting
tumor-associated antigens, and antibodies are
being increasingly used for the treatment of
various cancers. Saturable binding of antibody
with target antigen will lead to dose-dependencies
and time-dependencies in the site-selectivity of
antibody distribution, complicating efforts to
select dosing protocols that would provide the
greatest ratio of therapeutic benefit versus off-
site toxicity. Model-based approaches for dose-
selection have not come into common use, as fewFigure 6. Dose normalized concentration time profile
of T84.66 in the mice with or without LS174T xeno-
grafts. The solid line represents model simulated data
for control mice (25 mg/kg dose level), and the dashed-
dotted line indicates the model simulation for the 1 mg/
kg dose level in xenograft-bearing mice. Model simula-
tions for the 10 and 25 mg/kg doses, in tumor bearing
mice, are denoted by the dotted line and long dashed
line, respectively.
DOI 10.1002/jps JOUmechanistic models have been published to allow
the prediction or characterization of the effect of
antigen binding and target-mediated elimination
on the tissue-selectivity of antibody disposi-
tion.38,46–48 The present work was undertaken
to extend our previous model of antibody disposi-
tion, which accounts for the effects of FcRn on
IgG distribution and elimination, to incorporate
effects associated with specific binding to target
antigens. T84.66, a murine monoclonal anti-CEAFigure 8. Sensitivity analyses. The plots represent
the percent change in area under the T84.66 plasma
concentration time profile following 10% changes
selected parameter values. Small changes in model
output indicate that plasma exposure is relatively
insensitive to the adjusted parameter. Negative values
indicate a decrease in model output with increases in
the adjusted parameter. Symbols used along x-axis have
been included in Appendix I.
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Figure 9. Comparison of PBPK model-predicted ver-
sus observed tumor concentration. Simulations were
conducted to predict antibody concentrations in tumor
tissue following T84.66 doses of 1 and 10 mg/kg in
LS174T xenograft-bearing mice. Experimental data
were then obtained following administration of
125I-T84.66, with tumor concentrations determined
via gamma counting. Solid line represents model pre-
dictions at 1 mg/kg dose and dashed line is the model
predication at the 10 mg/kg dose. Data obtained from
individual mice are shown as closed symbols.
1592 URVA, YANG, AND BALTHASARIgG antibody, and LS174T, a human adenocarci-
noma that expresses CEA, were selected for
investigation.
In control animals that do not harbor LS174T
tumors, T84.66 exhibited linear elimination and
dose-proportional increases in plasma concentra-
tion over the dose-range of 1–25 mg/kg (Fig. 3). In
animals bearing LS174T tumors, T84.66 time-
averaged clearance was increased several fold,
consistent with target-mediated antibody elim-
ination (Fig. 5a–c).
Our previous PBPK model demonstrated the
importance of FcRn expressed in various tissues
such as skin, muscle, liver, gastrointestinal tract
and the kidneys on antibody pharmacokinetics.
This model was able to capture the plasma
pharmacokinetics of 7E3, a monoclonal IgG anti-
body, reasonably well.25 Of note, 7E3 is directed
against human glycoprotein IIb/IIIa, and the mAb
has no known specific binding target in mice.
Although the model provided good characteriza-
tion of the 7E3 data, there was some disagreement
between the model predictions and observed
values, especially at the initial time points.
Similarly, the prior PBPK model over-predicted
T84.66 concentrations in control mice lacking theJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARCH 2010tumor antigen. This prior PBPK model assumes
that antibody from interstitial compartment is
directly returned to the systemic circulation by
lymphatic drainage. This assumption may not be
completely valid, since it is known that lymph
outflow accumulates in the lymph nodes before
gaining access to the blood circulation. To improve
model performance, a lymph node transit com-
partment was incorporated. The transit time for
antibody movement through this lymph compart-
ment was characterized with the parameter Tau,
which was estimated to be 2.12 0.21 h. Inclusion
of this parameter allowed excellent characteriza-
tion of data obtained from tumor-free animals
(Fig. 4).
To account for the increased clearance of T84.66
in tumor-bearing animals, a target mediated
disposition component was incorporated into the
model. We assumed that the presence of the tumor
did not alter any of the physiological determinants
of antibody disposition (e.g., tissue volumes, blood
flow, convective transport, FcRn processing, etc.).
Differences in antibody disposition between con-
trol and tumor-bearing animals were assumed to
result from antibody binding to antigen, and by
the elimination of antibody bound to antigen
in tumor tissue. To account for tumor growth
following inoculation of tumor cells (Fig. 3), the
volumes of each tumor sub-compartment were
increased with time, using an exponential growth
function.
It is recognized that CEA that is shed from the
xenograft into the serum might lead to immune
complex formation with T84.66, thereby influen-
cing the pharmacokinetics of T84.66. However,
plasma collected from the tumor bearing mice
revealed CEA concentrations below the limit of
quantification for our assay, 2 ng/mL (0.01 nM),
which is far lower than the concentrations of
T84.66 observed at all time points, after each dose
of antibody. As such, shed CEA is not likely to be a
significant determinant of T84.66 disposition in
the LS174T xenograft model. Anti-drug antibo-
dies (ADA), generated against therapeutic mab,
may be important determinants of antibody
pharmacokinetics. ADA and therapeutic antibo-
dies may form complexes in vivo, leading to
rapid drug elimination via complement and/or
Fc-gamma-receptor pathways. The development
of an ADA response is thought to depend on
the nature of the dosing regimen (with greater
ADA development with chronic dosing), the
immune status of the recipient, the extent of
similarity between host immunoglobulin andDOI 10.1002/jps
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR T84.66 1593the therapeutic antibody, and the route of drug
administration (i.e., with greater ADA response
expected for SC dosing vs. IM dosing vs. IV
dosing). The extent of complexation and the
complex clearance rate are known to depend on
the size of immune complex formed, the concen-
tration of the drug, the concentrations of anti-
drug antibodies, and on the kinetics and stoichio-
metry of interaction between therapeutic anti-
body and anti-drug antibodies.49 Although not
measured, it is expected that there was little or no
ADA development in this study, as T84.66, a
mouse monoclonal antibody, was administered to
immuno-compromised nude mice as a single, IV
dose. Due to our expectations for minimal
potential for significant interaction between
soluble CEA and T84.66, and due to our expecta-
tions for a very low likelihood for development of
an anti-T84.66 antibody response, the model
presented in this article has not included a
pathway for immune-complex mediated elimina-
tion of anti-CEA antibody.
The model was able to capture the accelerated
clearance of T84.66 from plasma in the presence of
CEA-positive xenografts. The CV% of the para-
meters associated with the tumor compartment,
namely stumor, CLTMD, and FA, were less than 6%.
The estimated value of tumor vascular reflection
coefficient stumor was 0.842, which is less than the
value assumed for all other tissues (sV,organ: 0.95).
This parameter estimate is consistent with
the expectation that the tumor vasculature will
be highly permeable due to local secretion of
various vascular permeability enhancers, such as
vascular endothelial growth factor. Also, tumor
vessels are known to be dilated and leakier due to
the loss of the normal, continuous arrangement of
vascular cells in the tumor wall, thereby providing
decreased resistance to antibody uptake into the
interstitial compartment.
Sensitivity analyses indicate that the vascular
coefficient is indeed a very important parameter
governing plasma antibody concentrations. Addi-
tionally, tumor associated antigen concentration
and tumor antigen accessibility were important
determinants of plasma IgG concentration. This
is in accordance with published literature reports
which suggest that antigen distribution across a
tumor surface can be extremely heterogeneous
and successful antibody antigen binding can
also impede antibody transport.40,41 Importantly,
the model was less sensitive to parameters
associated with IgG binding to FcRn (e.g., FcRn
concentration and the recycling fraction ofDOI 10.1002/jps JOUIgG from the endosomal compartment). This
implies that in the presence of a significant
target mediated elimination pathway, FcRn
plays a minor role in determining antibody
disposition.
Other models describing IgG pharmacokinetics
in the presence of tumor have been published in
the literature. Baxter et al.32 compared the
pharmacokinetics of a tumor-specific antibody in
xenograft bearing mice with that of a nonspecific
antibody. This model, however, does not consider
the role of FcRn in protecting IgG from elimina-
tion and cannot account for the influence of
endogenous IgG concentrations and IgG-FcRn
binding affinity on antibody kinetics. In their
model, Baxter and Jain found that the tumor did
not significantly influence antibody pharmacoki-
netics. However, Halpern et al.,50 using the same
tumor model, demonstrated a faster initial loss of
the intact antibody from the blood of tumor
bearing mice compared to normal mice. This
difference in observations with the same tumor
model could be due to various factors such as the
specific antibody used, binding affinity, antigen
density, antigen shedding, size of tumor and the
time course of study. Also, the affinity of the
specific antibody to other antigens in normal
organs could greatly influence the pharmacoki-
netics. Ferl et al.51,52 published two articles
studying the influence of FcRn on pharmacoki-
netics of an anti-carcinoembryonic antibody and a
single-chain Fv antibody fragment. However,
they did not compare the pharmacokinetics of
the intact antibody in tumor bearing and control
mice, limiting their ability to investigate the
influence of antigen binding on anti-CEA antibody
disposition.
Due to complexities associated with the pro-
cesses of antibody distribution (e.g., determinants
of convection) and due to target-mediated elimi-
nation, it is often difficult to predict, a priori,
dose requirements for monoclonal antibodies to
achieve desired levels of target saturation. For
small molecule drugs, it is typical to assume
that drug distribution is predominantly controlled
by diffusion, and that steady-state unbound
concentrations of drug in plasma will be equiva-
lent to steady-state unbound drug concentrations
in tissues. As such, simple consideration of
input rate, plasma clearance, and receptor affinity
often allows useful projection of relationships
between dosage rates and receptor occupation.
However, in the case of macromolecule drugs,
such as antibodies, the efficiency of uptake intoRNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARCH 2010
1594 URVA, YANG, AND BALTHASARtissue via convection is much lower than the
efficiency of drug elimination from tissue via
convection. As such, drug concentration in
tissue interstitial fluid is typically much lower
than drug concentrations in plasma. Additionally,
when the macromolecule is subject to target-
mediated elimination, steady-state tissue inter-
stitial fluid concentrations may be further
reduced relative to plasma concentrations, poten-
tially by several logs. This lack of equivalence
between drug concentration in plasma and drug
concentrations in tissue fluid surrounding the
target receptor (i.e., the biophase) greatly com-
plicates efforts to predict dose levels of antibody to
produce a desired level of receptor occupancy or
effect.
Target-mediated disposition models are struc-
tured to allow consideration of the interaction of
drug with the target receptor, and such models
have been extremely useful in characterizing the
effect of drug–target interaction on nonlinear
drug distribution and elimination. However, the
initial, general target-mediated elimination mod-
els assumed that the target receptor is accessible
by drug in blood and, consequently, the simple
target-mediated disposition models13,48 do not
consider the complex interplay between rates of
antibody uptake into tissue, rates of antibody
elimination via convection and catabolism, and
receptor occupation. Conversely, PBPK models, as
shown in this manuscript, are well-suited for
consideration of the primary mechanisms asso-
ciated with antibody disposition (e.g., convection,
FcRn processing, target-mediated elimination),
and provide an efficient means of predicting tissue
concentrations and receptor occupation. For
example, in this study, peak plasma T84.66
concentrations following the 1 mg/kg dose were
more than 2000 times greater than the Kd for
T84.66-CEA binding (i.e., 90 nM vs. 0.038 nM).
Despite the high concentrations of antibody in
plasma, peak tumor concentrations were found to
less than 10 nM, well below the concentration of
CEA in tumor tissue (600 nM). The concentra-
tion of T84.66 in tumor tissue, which is much
lower than concentrations that would be antici-
pated based on consideration of plasma concen-
trations and receptor Kd, were well predicted by
the physiologically based model. Consistent with
the observed tumor concentration of T84.66, the
model predicts that a 1 mg/kg IV dose of antibody
will achieve a maximal receptor occupation of
0.32%, based on the model estimated quantity
of accessible CEA (i.e., FAnPtCEA), and a time-JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 3, MARCH 2010averaged receptor occupation of 0.14% for the
time interval of 0–24 h. The model also predicts
time-averaged occupation of 14.4% and 99.9% of
the available CEA for the 10 and 25 mg/kg
doses (0–24 h). It is important to note that the
predictions, which would be impossible to make
without the model structure, agree well with
the observed tumor concentration data collected
from the prospective model evaluation study
(Fig. 9).
Although the PBPK structure provides many
advantages, it is not very well suited for the
investigation of inter-individual variability in
antibody disposition following collection of sparse
samples from large clinical studies. The PBPK
model would allow mechanistic investigation
of known or suspected determinants of inter-
individual pharmacokinetic variability, perhaps
including the ‘‘body load’’ of tumor, the extent
of antigen expression on tumor tissue and on
healthy tissue, vascular permeability, tumor
blood flow, and rates of lymph flow.53 However,
due to the large number of parameters in the
model, and due to the potential for inter-
individual variability in each of the associated
physiological processes, PBPK models are not
likely to be useful for ‘‘population pharmacoki-
netic’’ analyses.CONCLUSION
T84.66, a murine monoclonal IgG anti-CEA anti-
body, demonstrates rapid elimination in tumor
bearing mice, consistent with target-mediated
antibody elimination. The disposition of T84.66
in control and tumor-bearing mice was well
described with a new PBPK model. This model
will be used in future work to evaluate drug
targeting strategies with T84.66, and the model
may find application in predicting antibody
disposition for inter-species scaling.ACKNOWLEDGMENTS
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APPENDIX I
Section I: Parameters associated with the basic physiologically based pharmacokinetic model (NO TUMOR)
Parameter Units Definition
Qorgan L/day Plasma flow rate to each organ
VVOrgan L Volume of vascular space
VEOrgan L Volume of endosomal space
V IOrgan L Volume of interstitial cell space layer
Vplasma L Mouse plasma volume
Cplasma nM Antibody concentration in plasma
CVOrgan nM Antibody concentration in vascular space in each tissue
CEOrgan nM Antibody concentration in endosomal space in each tissue
CIOrgan nM Antibody concentration in interstitial cell space layer
CTotalEndo;Organ nM Total antibody concentration in the endosomal space
CLorgan L/day Clearance of free antibody from endosomal layer
nPtorgan nM FcRn concentration in each organ
FR Recycling fraction of FcRn bound antibody
R1 1/day Endosomal uptake and return rate of antibody
sV,organ Vascular reflection coefficient
sI,organ Lymphatic reflection coefficient
Lorgan L/day Lymph flow rate
Kd nM Dissociation constant for antibody FcRn binding
fuorgan Unbound antibody fraction
Tau day Transit time for lymph transfer from lymph node to systemic circulation
Xlymph nmol Amount of antibody in the lymph node compartment
K0 M/min Endogenous antibody production rate
Section II: Additional parameters associated with the PBPK model in presence of tumor compartment
Parameter Units Definition
Kd-CEA nM Dissociation constant for antibody CEA binding
nPtCEA nM CEA concentration in tumor cell space layer
FA ‘‘Accessibility parameter’’ defines the fraction of antigen available for antibody binding
CLTMD L/min Clearance of antibody bound to CEA from cell space layer





¼ ððQlung  LlungÞ  CVlungÞ
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¼ ððQliver  LliverÞ  CVliverÞ þ ððQheart  LheartÞ  CVheartÞ þ ððQkidney  LkidneyÞ  CVkidneyÞ
þ ððQskin  LskinÞ  CVskinÞ þ ððQmuscle  LmuscleÞ  CVmuscleÞ
þ ððQtumor  LtumorÞ  CVtumorÞ þ ðFR  R1  ð1  fuLungÞ  CTotalEndoLung  VELungÞ





¼ ðR1  CVLung  VVLungÞ  ðfuLung  CLLung  CTotalEndo LungÞ





¼ ðð1  sVLungÞ  LLung  CVLungÞ þ ðð1  FRÞ  R1  ð1  fuLungÞ  CTotalEndo Lung  VELungÞ






¼ ððQgut  LgutÞ  CVgutÞ þ ððQspleen  LspleenÞ  CVspleenÞ
þ ððQliver  Qgut  Qspleen þ Lgut þ LspleenÞ  CplasmaÞ
þ ðFR  R1ð1  fuliverÞ  CTotalEndoLiver  VEliverÞ  ðR1  CVliver  VVliverÞ





¼ ðR1  CVliver  VVliverÞ  ðfuliver  CLliver  CTotalEndo LiverÞ





¼ ðð1  sVliverÞ  Lliver  CVliverÞ  ðð1  sIliverÞ  Lliver  CIliverÞ
þ ðð1  FRÞ  R1  CTotalEndo LiverÞ  ðR1  CIliver  V IliverÞ (7Þ
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¼ ðQorgan  CplasmaÞ þ ððFR  R1  ð1  fuorganÞÞ  CTotalEndoOrgan  VEorganÞ
 ðR1  CVorgan  VVorganÞ  ðð1  sVorganÞ  Lorgan  CVorganÞ





¼ ðR1  CVorgan  VVorganÞ  ðfuorgan  CLorgan  CTotalEndoOrganÞ





¼ ðð1  sVorganÞ  Lorgan  CVorganÞ  ðð1  sIorganÞ  Lorgan  CIorganÞ






¼ ðQtumor  CplasmaÞ þ ððFR  R1  ð1  futumorÞÞ  CTotalEndoTumor  VEtumorÞ
 ðR1  CVtumor  VVtumorÞ  ðð1  sVtumorÞ  Ltumor  CVtumorÞ





¼ ðR1  CVtumor  VVtumorÞ  ðfutumor  CLtumor  CTotalEndoTumorÞ
 ðð1  futumorÞ  R1  CTotalEndoTumor  VEtumorÞ þ ðR1  CItumor  fuinter  V ItumorÞ (12Þ




¼ ðð1  sVtumorÞ  Ltumor  CVtumorÞ  ðð1  fuinterÞ  CLTMD  CItumorÞ
 ðð1  sItumorÞ  Ltumor  CItumorÞ
þ ðð1  FRÞ  R1  ð1  futumorÞ  CTotalEndoTumor  VEtumorÞ  ðR1  CItumor  V ItumorÞ (13Þ
6. Lymph Node Compartment
dxlymph
dt
¼ ðð1  sIlungÞ  Llung  CIlungÞ þ ðð1  sIgutÞ  Lgut  CIgutÞ þ ðð1  sIspleenÞ  Lspleen  CIspleenÞ
þ ðð1  sIliverÞ  Lliver  CIliverÞ þ ðð1  sIheartÞ  Lheart  CIheartÞ
þ ðð1  sIkidneyÞ  Lkidney  CIkidneyÞ þ ðð1  sIskinÞ  Lskin  CIskinÞ
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For each organ the unbound fraction (fuorgan) is defined as follows:
(1) Unbound fraction in endosomal layer:










CTotalEndo; organ ¼ C
Endogenous
Endo; organ þ C
AntiCEA
Endo; organ (16Þ
The relationship for fuorgan was based on the following equilibrium equation:
25




FcRn  IgG (17Þ
(2) Similarly the unbound fraction (fuinter) in the interstitial layer of the tumor compartment is defined as
follows:
fuinter ¼ 1 
1
2  CTotalinter;tumor
 ½KdCEAtumor þ ðnPt
CEA







tumor  FAÞ þ CTotalInter; tumorÞ









CEA  IgG (19Þ
Eq. (18) is set up similar to Eq. (15) to determine the fraction of T84.66 unbound to the antigen CEA.
The term (nPtCEAtumor FA) denotes the fraction of carcinoembryonic antigen (CEA) available for binding
to T84.66 IgG.
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